Trials / Terminated
TerminatedNCT04517864
PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA
A PHASE 2a, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY INVESTIGATING THE SAFETY OF RITLECITINIB (PF-06651600) IN ADULT PARTICIPANTS WITH ALOPECIA AREATA
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 71 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
This is a global Phase 2a randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of ritlecitinib in adults aged 18 to ≤50 years of age with ≥25% scalp hair loss due to Alopecia Areata (AA).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PF-06651600 | 50 mg tablet, dosed as 200 mg QD or 50 mg QD 50 mg capsule, dosed as 50 mg QD |
| DRUG | Placebo | tablet, dosed as 4 tablets QD or 1 tablet QD |
Timeline
- Start date
- 2020-09-15
- Primary completion
- 2022-01-04
- Completion
- 2024-05-07
- First posted
- 2020-08-18
- Last updated
- 2025-07-11
- Results posted
- 2022-12-28
Locations
38 sites across 4 countries: United States, Australia, Canada, Poland
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04517864. Inclusion in this directory is not an endorsement.